ASAlison E. Simmons

Alison E. Simmons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison E. Simmons has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between seasonal respiratory virus activity and invasive pneumococcal disease in central Ontario, Canada

    by Alison E. Simmons, Isha Berry, Sarah A. Buchan, Ashleigh R. Tuite, David N. Fisman

    Background: In central Ontario, influenza, respiratory syncytial virus (RSV), and invasive pneumococcal disease (IPD) follow similar seasonal patterns, peaking in winter. We aimed to quantify the independent and joint impact of influenza A, influenza B, and RSV on IPD risk at the population level. Methods: We used a 2:1 self-matched case-crossover study design to evaluate acute effects of respiratory virus activity on IPD risk. This design ensures that effects are not confounded by within-individual characteristics that remain constant over short periods of time. We included 3,892 IPD cases occurring between January 2000 and June 2009. Effects were measured using univariable and multivariable conditional logistic regression. Multivariable models included environmental covariates (e.g., temperature, absolute humidity, and UV index) and interaction terms between viruses. Results: Influenza A activity and influenza B activity were both independently associated with increased IPD risk; however, co-circulation of influenza A and B reduced the impact of both viruses. RSV activity was positively associated with increased IPD risk only in the presence of increased influenza A or influenza B activity. Conclusions: To our knowledge this represents the first study to consider the impact of interactions between these viruses on IPD risk in Canada. Our findings suggest that the prevention of IPD should be considered as a potential health benefit of influenza and RSV vaccination programs.


  • Open Access

    Derivation and validation of a point-based forecasting tool for SARS-CoV-2 critical care occupancy: a population-based modeling study

    by Alicia A. Grima, Clara Eunyoung Lee, Ashleigh R. Tuite, Natalie J. Wilson, Alison E. Simmons, David N. Fisman


  • Open Access

    Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review of economic evaluations

    by Alison E Simmons, Raphael Ximenes, Gebremedhin B Gebretekle, Marina I Salvadori, Eva Wong, Ashleigh R Tuite

    In July 2024, Health Canada authorized a 21-valent pneumococcal conjugate vaccine (Pneu-C-21) for use in adults. To conduct a systematic review of the cost-effectiveness of Pneu-C-21 for preventing pneumococcal disease in adults. We conducted a systematic search of the literature and National Immunization Technical Advisory Groups’ websites on July 3, 2024. We included economic evaluations that assessed Pneu-C-21 as a vaccination strategy among adults aged 18 years and older. Costs were adjusted to 2023 Canadian dollars. We identified 10 studies in our search, five of which were summarized in our review. No economic evaluations were conducted in Canada. All economic evaluations used static cohort models and incorporated indirect effects from paediatric pneumococcal conjugate vaccination in primary or sensitivity analyses. Although incremental cost-effectiveness ratios were heterogeneous across included economic evaluations, overall, they qualitatively identified the same vaccination strategies as optimal within the given age and risk groups. Pneu-C-21 is likely to be cost-effective in adults aged 65 years and older and adults under the age of 65 years with specific high risk conditions. Pneu-C-21 is likely to be cost-effective in adults within specific age and risk groups. The applicability of the included economic evaluations to adults living in Canada is limited because the serotype-specific incidence of pneumococcal disease and the impact of indirect effects from pediatric vaccination varies by region and over time.


  • Open Access

    Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada

    by Alison E. Simmons, Rafael N. Miranda, Michael W.Z. Li, Gebremedhin B. Gebretekle, Min Xi, Marina I. Salvadori, Bryna Warshawsky, Eva Wong, Raphael Ximenes, Melissa K. Andrew, et al.

    Background: As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-19 vaccination program similar to current Canadian recommendations, modelled as annual vaccination for people aged less than 65 years with chronic medical conditions and biannual vaccination for adults aged 65 years and older. Methods: Using a static individual-based model of medically attended COVID-19 in a population of 1 million people, we estimated costs (in 2023 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used health system and societal perspectives and a 1.5% discount rate. Parameters were based on recent COVID-19 epidemiology, vaccine characteristics, and costs. Results: Between July 2024 and September 2025, a program similar to current Canadian recommendations was estimated to avert 3.1% (95% credible interval (CrI): 3.0 to 3.2%) of outpatient cases, 8.8% (95% CrI: 7.3 to 10.4%) of inpatient cases, 3.6% (95% CrI: 2.8 to 4.3%) of PCC cases, and 9.4% (95% CrI: 5.6 to 13.8%) of deaths compared to no vaccination. The number needed to vaccinate to prevent one hospitalization and one death was 1,121 (95% CrI: 941 to 1,357) and 8,656 (95% CrI: 5,848 to 14,915), respectively. For the health system perspective, the program would cost an additional $4.695 million but result in 221.17 QALYs gained, leading to an ICER of $21,227 per QALY compared to no vaccination. Vaccine price influenced cost-effectiveness, with higher prices reducing the likelihood the program met common cost-effectiveness thresholds. Conclusions: A program similar to current COVID-19 recommendations in Canada is likely effective and cost-effective compared to no vaccination. However, unlike some other research studies, alternate vaccination strategies that may offer better value for money were not evaluated.


  • Open Access

    Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-CoV-2 circulation in Canada

    by Rafael N. Miranda, Alison E. Simmons, Michael W.Z. Li, Gebremedhin B. Gebretekle, Min Xi, Marina I. Salvadori, Bryna Warshawsky, Eva Wong, Raphael Ximenes, Melissa K. Andrew, et al.

    Background: With shifting epidemiology and changes in the vaccine funding landscape, resource use considerations for ongoing COVID-19 vaccination programs are increasingly important. We assessed the cost-effectiveness of COVID-19 vaccination programs, where eligibility is defined by combinations of age and chronic medical conditions, including a strategy similar to current Canadian recommendations, from the health system and societal perspectives. Methods: We used a static, individual-based probabilistic model simulating medically attended COVID-19 in a population of 1 million people followed over a 15-month time period to estimate costs in 2023 Canadian dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 1.5%. COVID-19 epidemiology, vaccine characteristics, and costs were based on the most recently available data. Results: Annual vaccination for adults aged 65 years and older consistently emerged as a cost-effective intervention, with ICERs less than $50,000 per QALY compared to no vaccination for a range of model assumptions. Adding a second dose for adults aged 65 years and older or expanding programs to include vaccination for younger age groups, including those at higher risk of COVID-19 due to chronic medical conditions, generally resulted in ICERs of greater than $50,000 per QALY. Shifting timing of vaccination programs to better align with periods of high COVID-19 case occurrence could result in biannual vaccination for those aged 65 and older being a cost-effective strategy. Conclusions: COVID-19 vaccination programs may be cost-effective when focused on groups at higher risk of disease. Optimal timing of vaccination could improve the cost-effectiveness of various strategies.


  • Open Access

    Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada

    by Raphael Ximenes, Alison E. Simmons, Gebremedhin B. Gebretekle, Austin Nam, Eva Wong, Marina I. Salvadori, Alyssa R. Golden, Beate Sander, Kyla J. Hildebrand, Matthew Tunis, et al.

    Background: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). Objective: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups. Methods: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5%, in population cohorts aged 33 (midpoint of the 18-49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015-2019, to explore the impact of changes over time observed in some age groups. Results: For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50-64 years with additional risk factors for IPD, or 18-49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50-64 years without additional IPD risk factors and 18-49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios. Interpretation: The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.

  • Open Access

    Association Between Seasonal Respiratory Virus Activity and Invasive Pneumococcal Disease in Central Ontario, Canada

    by Alison E. Simmons, Isha Berry, Sarah A. Buchan, Ashleigh R. Tuite, David N. Fisman

    Background In central Ontario, influenza, respiratory syncytial virus (RSV), and invasive pneumococcal disease (IPD) follow similar seasonal patterns, peaking in winter. We aimed to quantify the independent and joint impact of influenza A, influenza B, and RSV on IPD risk at the population level. Methods We used a 2:1 self-matched case-crossover study design to evaluate acute effects of respiratory virus activity on IPD risk. This design ensures that effects are not confounded by within-individual characteristics that remain constant over short periods of time. We included 3,892 IPD cases occurring between January 2000 and June 2009. Effects were measured using univariable and multivariable conditional logistic regression. Multivariable models included environmental covariates (e.g., temperature, absolute humidity, and UV index) and interaction terms between viruses. Results Influenza A activity and influenza B activity were both independently associated with increased IPD risk; however, co-circulation of influenza A and B reduced the impact of both viruses. RSV activity was positively associated with increased IPD risk only in the presence of increased influenza A or influenza B activity. Conclusions To our knowledge this represents the first study to consider the impact of interactions between these viruses on IPD risk in Canada. Our findings suggest that the prevention of IPD should be considered as a potential health benefit of influenza and RSV vaccination programs.


  • Open Access

    Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: a multi-model comparison

    by Monica Rudd, Alison E. Simmons, Gebremedhin B. Gebretekle, Ashleigh R. Tuite

    Background Two respiratory syncytial virus (RSV) vaccines are currently approved for use in adults aged 60 years and older in Canada. Economic analyses have shown that adult RSV vaccination programs may be cost-effective, particularly when focused on people at increased risk of RSV disease due to increased age or presence of chronic medical conditions (CMCs). We conducted a multi-model comparison to explore the impact of alternate model structural and methodological assumptions on the cost-effectiveness of RSV vaccination programs. Methods We compared three static cost-utility models developed by the Public Health Agency of Canada, GSK, and Pfizer using a common set of input parameters. Each model evaluated sequential incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjusted life year (QALY) for a set of policy alternatives, with vaccine eligibility determined by combinations of age and CMC status. Results were calculated for each vaccine separately for scenarios assuming two or three years of vaccine protection using the health system perspective and a 1.5% annual discount rate. Results The three cost-utility models were broadly concordant across the scenarios modeled. In all scenarios, focusing on vaccination of people with CMCs was preferred over broader age-based policies. RSV vaccination for people with CMCs over the age of 70 years was most commonly identified as the optimal policy when using a cost-effectiveness threshold of $50,000/QALY. When only considering policies based on age criteria, vaccinating people over 80 years was cost-effective at this threshold. Discussion A multi-model comparison of Canadian cost-utility models shows that RSV vaccination programs for RSV are likely cost-effective for some groups of older adults in Canada. These findings were consistent across models, despite differences in model structure.


  • Open Access

    Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority

    by David N. Fisman, Afia Amoako, Alison Simmons, Ashleigh R. Tuite

    Background: We previously demonstrated that when vaccines prevent infection, the dynamics of mixing between vaccinated and unvaccinated sub-populations is such that use of imperfect vaccines markedly decreases risk for vaccinated people, and for the population overall. Risks to vaccinated people accrue disproportionately from contact with unvaccinated people. In the context of the emergence of Omicron SARS-CoV-2 and evolving understanding of SARS-CoV-2 epidemiology, we updated our analysis to evaluate whether our earlier conclusions remained valid. Methods: We modified a previously published Susceptible-Infectious-Recovered (SIR) compartmental model of SARS-CoV-2 with two connected sub-populations: vaccinated and unvaccinated, with non-random mixing between groups. Our expanded model incorporates diminished vaccine efficacy for preventing infection with the emergence of Omicron SARS-CoV-2 variants, waning immunity, the impact of prior immune experience on infectivity, “hybrid” effects of infection in previously vaccinated individuals, and booster vaccination. We evaluated the dynamics of an epidemic within each subgroup and in the overall population over a 10-year time horizon. Results: Even with vaccine efficacy as low as 20%, and in the presence of waning immunity, the incidence of COVID-19 in the vaccinated subpopulation was lower than that among the unvaccinated population across the full 10-year time horizon. The cumulative risk of infection was 3–4 fold higher among unvaccinated people than among vaccinated people, and unvaccinated people contributed to infection risk among vaccinated individuals at twice the rate that would have been expected based on the frequency of contacts. These findings were robust across a range of assumptions around the rate of waning immunity, the impact of “hybrid immunity”, frequency of boosting, and the impact of prior infection on infectivity in unvaccinated people. Interpretation: Although the emergence of the Omicron variants of SARS-CoV-2 has diminished the protective effects of vaccination against infection with SARS-CoV-2, updating our earlier model to incorporate loss of immunity, diminished vaccine efficacy and a longer time horizon, does not qualitatively change our earlier conclusions. Vaccination against SARS-CoV-2 continues to diminish the risk of infection among vaccinated people and in the population as a whole. By contrast, the risk of infection among vaccinated people accrues disproportionately from contact with unvaccinated people.


  • Open Access

    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants

    by Gebremedhin B. Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis, et al.

    Background Health Canada recently authorized the RSVpreF pregnancy vaccine and nirsevimab to protect infants against respiratory syncytial virus (RSV) disease. Objective Assess the cost-effectiveness of RSVpreF and nirsevimab programs in preventing RSV disease in infants, compared to a palivizumab program. Methods We used a static cohort model of a Canadian birth cohort during their first RSV season to estimate sequential incremental cost-effectiveness ratios (ICERs) in 2023 Canadian dollars per quality-adjusted life year (QALY) for nine strategies implemented over a one-year time period, from the health system and societal perspectives. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties on the results. Results All-infants nirsevimab programs averted more RSV-related outcomes than year-round RSVpreF programs, with the most RSV cases averted in seasonal nirsevimab programs. Assuming list prices for these immunizing agents, all-infants nirsevimab and year-round RSVpreF programs were never cost-effective, with ICERs far exceeding commonly used cost-effectiveness thresholds. Seasonal nirsevimab with catch-up was cost-effective if prioritized for infants at moderate/high-risk (ICER <$28,000 per QALY) or those living in settings with higher RSV burden and healthcare costs (ICER of $5,700 per QALY). Using a $50,000 per QALY threshold, an all-infants nirsevimab program could be optimal if nirsevimab is priced at <$110-190 per dose. A year-round RSVpreF for all pregnant women/pregnant people plus nirsevimab for infants at high-risk was optimal if nirsevimab is priced at >$110-190 and RSVpreF priced at <$60-125. Interpretation Prophylactic interventions can substantially reduce RSV disease in infants, and targeted nirsevimab programs are the most cost-effective option at current product prices.